Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $17.93.

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th.

Insider Buying and Selling

In related news, CIO Mayukh Sukhatme sold 689,495 shares of Roivant Sciences stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.01, for a total value of $8,280,834.95. Following the sale, the executive now owns 18,836,547 shares of the company’s stock, valued at approximately $226,226,929.47. This trade represents a 3.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the transaction, the chief operating officer now owns 606,525 shares of the company’s stock, valued at $6,865,863. This represents a 14.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,942,629 shares of company stock valued at $23,071,486. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Roivant Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC increased its stake in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after buying an additional 2,593,910 shares in the last quarter. Rubric Capital Management LP increased its position in shares of Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock worth $243,110,000 after purchasing an additional 3,000,000 shares in the last quarter. State Street Corp raised its stake in Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after purchasing an additional 1,118,561 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after purchasing an additional 1,460,205 shares in the last quarter. Finally, DME Capital Management LP boosted its stake in Roivant Sciences by 14.8% during the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock worth $50,852,000 after purchasing an additional 620,470 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Down 4.3 %

Shares of Roivant Sciences stock opened at $11.02 on Friday. The firm has a market capitalization of $8.02 billion, a P/E ratio of 1.95 and a beta of 1.27. Roivant Sciences has a 52 week low of $9.69 and a 52 week high of $13.06. The company has a 50 day moving average price of $11.89 and a 200 day moving average price of $11.58.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.